A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays

被引：29

作者：

Carlsson, SC ^{[1
]}

Mattsson, C

Eriksson, UG

Sarich, TC

Wåhlander, K

Eliasson, Å

Karlson, BW

Sheth, SB

Held, P

机构：

[1] AstraZeneca R&D, Molndal, Sweden

[2] AstraZeneca LP, Wilmington, DE USA

来源：

THROMBOSIS RESEARCH | 2005年 / 115卷 / 1-2期

关键词：

activated clotting time; activated partial thromboplastin time; blood coagulation tests; ecarin clotting time; oral direct thrombin inhibitors; prothrombin time; thrombin clotting time; ximelagatran;

D O I：

10.1016/j.thromres.2004.07.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：9 / 18

页数：10

共 60 条

[1]

Albers GW, 2003, LANCET, V362, P1691

[2] Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral Ximelagatran -: A multicentre study of thromboprophylaxis in elective abdominal surgery [J].

Bergqvist, D ;

Solhaug, JH ;

Holmdahl, L ;

Eriksson, UG ;

Andersson, M ;

Boberg, B ;

Ögren, M .

CLINICAL DRUG INVESTIGATION, 2004, 24 (03) :127-136

[3] Inhibition of thrombin-induced feedback activation of factor V:: a potential pathway for inhibition of thrombin generation by melagatran [J].

Boström, SL ;

Dagnelid, E ;

Hansson, GFH ;

Ulvinge, JC .

BLOOD COAGULATION & FIBRINOLYSIS, 2004, 15 (01) :25-30

[4] Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions [J].

Bredberg, E ;

Andersson, TB ;

Frison, L ;

Thuresson, A ;

Johansson, S ;

Eriksson-Lepkowska, M ;

Larsson, M ;

Eriksson, UG .

CLINICAL PHARMACOKINETICS, 2003, 42 (08) :765-777

[5] Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time [J].

de Denus, S ;

Spinler, SA .

PHARMACOTHERAPY, 2002, 22 (04) :433-435

[6] EFFECTS OF RECOMBINANT HIRUDIN (R-HIRUDIN, HBW-023) ON COAGULATION AND PLATELET ACTIVATION IN-VIVO - COMPARISON WITH UNFRACTIONATED HEPARIN AND A LOW-MOLECULAR-WEIGHT HEPARIN PREPARATION (FRAGMIN) [J].

EICHINGER, S ;

WOLZT, M ;

SCHNEIDER, B ;

NIESZPAURLOS, M ;

HEINRICHS, H ;

LECHNER, K ;

EICHLER, HG ;

KYRLE, PA .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (07) :886-892

[7] Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement:: the METHRO II randomised trial [J].

Eriksson, B ;

Bergqvist, D ;

Kälebo, P ;

Dahl, OE ;

Lindbratt, S ;

Bylock, A ;

Frison, L ;

Eriksson, UG ;

Welin, L ;

Gustafsson, D .

LANCET, 2002, 360 (9344) :1441-1447

[8] The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement:: the EXPRESS study [J].

Eriksson, BI ;

Agnelli, G ;

Cohen, AT ;

Dahl, OE ;

Lassen, MR ;

Mouret, P ;

Rosencher, N ;

Kälebo, P ;

Panfilov, S ;

Eskilson, C ;

Andersson, M .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (12) :2490-2496

[9]

Eriksson BI, 2003, THROMB HAEMOSTASIS, V89, P288

[10] Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans [J].

Eriksson, UG ;

Bredberg, U ;

Hoffmann, KJ ;

Thuresson, A ;

Gabrielsson, M ;

Ericsson, H ;

Ahnoff, M ;

Gislén, K ;

Fager, G ;

Gustafsson, D .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :294-305

← 1 2 3 4 5 6 →